Vivos Therapeutics Q4 Earnings Call Highlights

Vivos Therapeutics (NASDAQ: VVOS) executives told investors the company's shift toward a medical provider-focused model, anchored by the June 2025 acquisition of the Sleep Center of Nevada (SCN), drove higher revenue in 2025 and is reshaping its growth strategy heading into 2026. 2025 results reflect SCN acquisition and model pivot Chief Financial Officer Bradford Amman said